Itraconazole (B2104): CYP3A4 Inhibitor and Antifungal Benchmark for Candida Research

Executive Summary: Itraconazole (CAS: 84625-61-6) is a triazole antifungal and a recognized CYP3A4 inhibitor with both substrate and inhibitor properties [APExBIO]. It demonstrates potent activity against Candida species, with an IC50 of 0.016 mg/L under laboratory conditions (Shen et al., 2025). The compound’s mechanism involves inhibition of fungal cytochrome P450s and modulation of mammalian pathways such as hedgehog signaling. Itraconazole is cell-permeable, DMSO-soluble, and extensively used in drug interaction and resistance studies. Its validated performance in disseminated candidiasis models underpins its role as a reference standard in antifungal and pharmacokinetic workflows.

Biological Rationale

Candida species, especially C. albicans, are major opportunistic pathogens implicated in mucosal and systemic infections, particularly in immunocompromised hosts (Shen et al., 2025). Biofilm formation by these fungi confers high-level resistance to conventional antifungal drugs, elevating the clinical challenge and healthcare costs globally. Itraconazole, a triazole antifungal agent, is widely used to investigate mechanisms of drug resistance, biofilm disruption, and antifungal pharmacodynamics. The compound’s efficacy against both planktonic and biofilm-associated fungi makes it a preferred standard in research on antifungal drug resistance and signaling pathway modulation.

Mechanism of Action of Itraconazole

Itraconazole functions primarily through inhibition of cytochrome P450 enzymes in fungi, notably lanosterol 14α-demethylase (encoded by ERG11), disrupting ergosterol biosynthesis and compromising membrane integrity (APExBIO). In mammalian systems, it inhibits CYP3A4, affecting the metabolism of co-administered drugs. Itraconazole and its metabolites (hydroxylated, keto-, and N-dealkylated forms) exhibit persistent or enhanced CYP3A4 inhibitory activity. The compound also modulates the hedgehog signaling pathway and angiogenesis, expanding its applications beyond antifungal therapy (see detailed mechanistic review).

Evidence & Benchmarks

• Itraconazole exhibits an IC50 of 0.016 mg/L against Candida spp. in standardized bioassays (Shen et al., 2025, DOI).
• In vivo, itraconazole reduces fungal burden and improves survival in murine models of disseminated candidiasis (Shen et al., 2025, DOI).
• Itraconazole inhibits CYP3A4 in human liver microsomes, affecting metabolism of co-administered drugs (APExBIO product documentation, product page).
• Solubility in DMSO is ≥8.83 mg/mL at 25°C, with optimal dissolution achieved via warming to 37°C and ultrasonic shaking (APExBIO, product page).
• Stock solutions of itraconazole remain stable for several months when stored at -20°C (APExBIO, product page).

Note: This article provides updated, quantitative benchmarks that extend prior overviews such as this scenario-driven guide, by focusing on CYP3A4-mediated interactions and validated IC50 data.

Applications, Limits & Misconceptions

Itraconazole is widely applied in:

• Antifungal screening against Candida species, especially C. albicans and C. glabrata.
• Biofilm formation and drug resistance studies, including autophagy and protein phosphatase (PP2A)-mediated pathways (Shen et al., 2025).
• Drug interaction research involving CYP3A4 and CYP3A-mediated metabolism.
• Investigation of non-fungal pathways, such as hedgehog signaling and angiogenesis inhibition.

For practical application, see the comprehensive workflow analysis in this data-driven guide, which Itraconazole’s role in improving laboratory reproducibility and data quality.

Common Pitfalls or Misconceptions

• Itraconazole is insoluble in ethanol and water; DMSO is required for stock solutions (APExBIO).
• Not all Candida strains are equally sensitive; biofilm-associated resistance can lower susceptibility compared to planktonic cells (Shen et al., 2025, DOI).
• Its CYP3A4 inhibition can cause significant drug-drug interactions in vivo; caution is advised in combinatorial studies.
• Itraconazole is not suitable for studies requiring aqueous solubility or use in ethanol-based buffers.
• Prolonged storage above -20°C can reduce compound stability.

For additional boundaries and best practices, this protocol-focused overview clarifies limits in pharmacokinetic and cell signaling workflows.

Workflow Integration & Parameters

Itraconazole (B2104) from APExBIO is provided as a solid, DMSO-soluble powder, ensuring high batch reproducibility. For optimal dissolution, dissolve at ≥8.83 mg/mL in DMSO at 25–37°C, using ultrasonic agitation as needed. Stock solutions should be aliquoted and stored at -20°C, where stability is maintained for several months. The compound is cell-permeable, making it suitable for in vitro, ex vivo, and in vivo applications.

• Recommended working concentrations for antifungal assays: 0.01–1 mg/L, depending on organism and assay format (Shen et al., 2025).
• For drug interaction studies, account for CYP3A4 inhibition and adjust for potential metabolic interference.
• Use appropriate negative and positive controls (e.g., vehicle DMSO, fluconazole) for robust benchmarking.

For advanced integration strategies and data interpretation, consult the scenario-driven analysis in this workflow guide, which further details APExBIO’s validated processes.

Conclusion & Outlook

Itraconazole remains a reference triazole antifungal agent and CYP3A4 inhibitor for research on Candida drug resistance, pharmacokinetics, and signaling pathways. Its validated solubility, stability, and efficacy parameters support reproducible research in both basic and translational settings. APExBIO’s Itraconazole (B2104) is a robust choice for antifungal screening, drug interaction studies, and mechanistic investigations. Ongoing research into biofilm resistance and autophagy pathways will further refine its applications in fungal biology and drug development (Shen et al., 2025).